Medicare GLP-1 Bridge Program: $50/Month: Now Live as of July 1, 2026
As of July 1, 2026, Medicare Part D beneficiaries can now get Foundayo, Wegovy, and Zepbound KwikPen at a flat $50/month copay through the Medicare GLP-1 Bridge demonstration, confirmed by CMS, NPR, and KFF. The program runs through December 31, 2027.
The $50 copay does not count toward the Part D deductible or the $2,100 annual out-of-pocket cap. Prior authorization is required and processed through Humana (CMS's designated central processor via LI NET infrastructure).
Free 60-second check. No sign-up needed.
Does Medicare cover it? At a glance
| Drug | Covered? | How / cost |
|---|---|---|
| Zepbound (KwikPen only) $50/mo copay via Part D Bridge, July 1, 2026 to Dec 31, 2027. Vials + single-dose pens NOT covered. | Yes | $50/mo copay via Part D Bridge, July 1, 2026 to Dec 31, 2027. Vials + single-dose pens NOT covered. |
| Wegovy (injection + oral tablet) $50/mo copay via Part D Bridge, all formulations, July 1, 2026 to Dec 31, 2027. | Yes | $50/mo copay via Part D Bridge, all formulations, July 1, 2026 to Dec 31, 2027. |
| Foundayo (orforglipron) $50/mo copay via Part D Bridge, all formulations of the once-daily oral GLP-1. | Yes | $50/mo copay via Part D Bridge, all formulations of the once-daily oral GLP-1. |
| Ozempic Covered by your regular Part D plan for type 2 diabetes only. Not FDA-approved or covered for weight loss. | T2D only | Covered by your regular Part D plan for type 2 diabetes only. Not FDA-approved or covered for weight loss. |
| Compounded semaglutide / tirzepatide Not covered by the Bridge or Part D. Cash-pay only, see cheapest providers below. | No | Not covered by the Bridge or Part D. Cash-pay only, see cheapest providers below. |
Sources and full detail in which drugs are covered below. If you don't qualify, cash-pay options start around $99/mo.
Bridge enrollment alerts
Medicare GLP-1 coverage changes constantly. Get an email when Bridge enrollment rules, covered drugs, or the post-2027 outlook change.
Free. No affiliate spam. Unsubscribe in one click.
Which drugs are covered?
The at-a-glance table above gives the yes/no answer. Here's the detail on the four Bridge-covered products, including the Zepbound restriction: only the KwikPen formulation qualifies.
Source: CMS Medicare GLP-1 Bridge, NPR May 2026, KFF
Which Medicare plans qualify?
Part D sponsors do not have to opt in. The Bridge runs as a separate CMS demonstration. Any beneficiary enrolled in one of the five eligible plan types automatically has access.
How prior authorization works
Humana is the single central processor for all Bridge prior authorizations and claims adjudication. This is the same Humana infrastructure that already runs the LI NET (Low-Income Newly Eligible Transition) program for CMS.
CMS released the official prior authorization request form on June 8, 2026. It specifies a two-step sequence:
- Your pharmacy first runs a claim against the dedicated Bridge processor (BIN 028918, PCN MEDDGLP1BR) and receives a denial, that denied claim opens the prior-auth pathway.
- Your prescriber then files the CMS form electronically via CoverMyMeds or by fax. Only prescribing clinicians can submit; beneficiaries cannot self-file.
- The PA routes through Humana for central processing regardless of your specific plan.
- Once approved, you fill the prescription at any participating pharmacy at the $50 copay.
If you were already on a GLP-1 at a higher BMI and have since lost weight, the form instructs your prescriber to record your initial BMI at the time therapy started.
Where you actually fill it
Approval and access are two different problems. The Bridge bills on its own rail, so the question of which pharmacy will run that claim is a real one, and until August 2026 almost no coverage answered it.
Amazon says it now delivers Wegovy (injection and tablet), Zepbound KwikPen and Foundayo to eligible Medicare Part D patients at the $50 monthly copay, with free home delivery and no Prime membership required. It puts Same-Day Delivery in more than 3,100 US cities and towns, expanding to nearly 4,500 by the end of 2026, and says eligibility verification, prior authorization and billing are handled automatically once your clinician sends the e-prescription. Those are Amazon's figures for Amazon's own service, not a CMS statement, and the Bridge is not exclusive to any pharmacy: the $50 copay applies at any participating pharmacy that can bill the demonstration. We have seen headlines naming other national chains, but no primary confirmation, so we are not listing any others until there is one.
Source: Amazon, August 2026
- 1 Your prescriber has to certify a lifestyle program. Medicare requires the clinician to attest that the GLP-1 is being used as part of a program focused on diet and exercise. A prescription on its own is not enough.
- 2 One prior authorization covers you through December 31, 2027. It stays valid for refills and for dose changes. Switching to a different GLP-1 is what forces a new one.
- 3 You fill one month at a time. Either 28 or 30 days depending on the drug. There is no 90-day fill on the Bridge.
- 4 The $50 is money you will not get back anywhere else. Because the Bridge sits outside the Part D benefit, the copay does not touch your deductible or your out-of-pocket limit, never appears on your Part D Explanation of Benefits or your Medicare Summary Notice, cannot be reduced by Extra Help, and cannot be spread across months through the Medicare Prescription Payment Plan.
Source: Medicare.gov, Weight loss drugs, CMS Medicare GLP-1 Bridge FAQs. Verified August 10, 2026.
Who qualifies, and the comorbidity twist
- ✓ Enrolled in Medicare Part D (PDP, MA-PD, SNP, EGWP, or LI NET)
- ✓ Age 65+ OR disability via SSDI (24+ months) OR End-Stage Renal Disease
- ✓ Tier 1, BMI ≥ 35, no additional diagnosis required
- ✓ Tier 2, BMI ≥ 30 with HFpEF, uncontrolled hypertension, or CKD stage 3a+
- ✓ Tier 3, BMI ≥ 27 with pre-diabetes, prior MI, prior stroke, or symptomatic PAD
Not sure which tier you fall in? Enter your height and weight.
Rule of thumb: BMI 30+, or 27+ with a weight-related condition, generally qualifies for GLP-1 weight-management treatment.
Educational estimate only, not medical advice or a diagnosis. Your prescriber confirms eligibility. Full check: eligibility checker.
How many people actually qualify, and what it costs if you do not
Medicare has never published an enrollment figure for the Bridge. The closest thing to a size is KFF's analysis of 2023 claims: of the 9.7 million Part D enrollees who met the clinical criteria, 3.8 million met every eligibility rule. The other 5.9 million qualify on their weight and are shut out on their diagnosis. Treat these as orders of magnitude rather than a headcount. They are modelled on 2023 data and assume nobody's diagnoses or GLP-1 use changed by 2026, which is not a safe assumption in a category growing this fast.
Source: Juliette Cubanski and Nolan Sroczynski, KFF, June 29, 2026. KFF also sized the program's cost to Medicare: $1.3bn to $3.3bn over 18 months at 10-25% participation, $6.7bn to $10bn at 50-75%.
Being excluded is a routing rule, not a judgement about need
The three diagnoses that route you off the Bridge, listed in full in the eligibility section above, do not mean Medicare has decided you need the drug less. They mean your own Part D plan might already cover a GLP-1 to treat that condition, so Medicare sends the request there instead. The catch is that "might already cover" is doing a lot of work. Your plan decides, on its own formulary, and the Bridge's $50 flat copay does not follow you.
If you are one of the 5.9 million, here is what you actually pay
Through Part D. KFF Health News reported on August 25, 2026 that GLP-1 copays for Medicare patients routed back to their drug plan "can run them $200 to $600 a month, if not more." That is 4 to 12 times the Bridge copay for the same molecule. The same reporting followed a 68-year-old denied the Bridge because of severe obstructive sleep apnea whose denial notice did not say why he had been rejected. If you are denied, ask your plan in writing which coverage determination was applied and what your Part D appeal rights are, because the notice may not tell you on its own.
Paying cash instead. Both manufacturers sell direct at prices far below a list-price pharmacy counter. NovoCare lists Wegovy at pen $199/mo for the first two 0.25 mg or 0.5 mg fills through December 31, 2026, then $349/mo at standard strengths or $399/mo for Wegovy HD; oral pill from $149/mo, dose-dependent. LillyDirect lists Foundayo (orforglipron) at $149/mo at 0.8 mg; $199/mo at 2.5 mg; $299/mo at 5.5 mg or 9 mg; $299/mo at 14.5 mg or 17.2 mg when refilled within 45 days, otherwise $349/mo. Neither is $50, and cash spending does not touch your Part D deductible or your $2,100 out-of-pocket cap. But at the starting strengths, both undercut the $200 to $600 Part D range above.
Sources: Jackie Fortiér, KFF Health News, August 25, 2026. Cash prices are our own manufacturer-channel tracking of NovoCare and LillyDirect, re-verified August 2026. Programs and eligibility change; confirm at checkout.
Does the 2027 Medicare negotiated price fix this?
Partly, and only for one of the three Bridge drugs. CMS announced on November 25, 2025 that semaglutide is in the second cycle of Medicare drug price negotiation. Ozempic, Rybelsus and Wegovy are treated as one selected drug because they share an active ingredient, and the agreed price is $274 for a 30-day supply, a 71% discount from the $959 CY2024 list price, effective January 1, 2027.
Three things that headline number does not tell you.
1. It is not one price. $274 is the 30-day-supply figure for the group. CMS's own per-package file puts the Ozempic 4 mg/3 mL pen and the Rybelsus 7 mg 30-tablet pack at $276.78 each, and the Wegovy 2.4 mg/0.75 mL four-pen pack at $385.63. On a page about Wegovy, that is the number that matters.
2. It is not a copay. The Maximum Fair Price is what the pharmacy is paid. What you pay still depends on your plan's deductible, your coinsurance tier, where you sit in the benefit year and whether your plan covers the drug for your indication at all. That gap is exactly why excluded beneficiaries are quoted $200 to $600 a month today against a list price the negotiation is cutting.
3. It is semaglutide only. This page covers three drugs and only one is in the negotiation cycle. Zepbound (tirzepatide) and Foundayo (orforglipron) are not on the selected-drug list and have no negotiated price. If you are on either of those, nothing about 2027 changes your cost.
Source: CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet, retrieved August 26, 2026). Separately, Novo Nordisk and Eli Lilly agreed a $245/month most-favored-nation net price with the administration. That is a different mechanism from the IRA negotiation and a different number; see our Medicare coverage guide.
Medicare negotiated $274 for a 30-day semaglutide supply starting in 2027. A cash payer buying the Wegovy oral tablet through NovoCare today starts at $149 a month, which is already below that, and well below the $385.63 CMS set for the Wegovy pen package. A Bridge-eligible beneficiary pays $50, under a fifth of the negotiated price.
These are not like-for-like. $50 and $149 are what a person hands over; $274 is what Medicare pays a pharmacy, before your plan decides your share. The honest read is narrower and more useful: the 2027 negotiation is a win for the Medicare program's budget, and it is not the thing that rescues the 5.9 million people this section is about. For them the live options are their own Part D plan at $200 to $600, or the manufacturer cash channel. Compare cash-pay prices across every provider we track.
How many prescriptions the Bridge is actually filling
Two national pharmacy chains have put the first quantity on this programme. CVS and Walgreens each told NPR they had filled around 100,000 Bridge prescriptions since the July 1, 2026 launch, reported August 26, 2026, less than two months in. CVS's own wording is more than 100,000 as of mid-August. Read those as prescription fills counted by two retailers. They are not a headcount of people, and they are not a CMS figure.
Source: Sydney Lupkin, NPR, August 26, 2026. Figures are what each chain says about its own dispensing, not an audited or official count.
Why a fill is not a person, and why 200,000 is not the programme
A fill is not a patient. The Bridge dispenses one month at a time and has no 90-day fill, which is set out in the mechanics above. A beneficiary who started in July is therefore already more than one of these fills, and nobody has published how many fills the average Bridge patient accounts for. So the count is not a headcount and cannot honestly be converted into one.
Two chains are not the market. These are two retailers' counts of their own dispensing. Walmart and Sam's Club declined a number, mail order and the Amazon Pharmacy channel are not in it, and no one has published what share of Bridge volume CVS and Walgreens represent. The two figures are a floor under total fills and nothing more.
Set against the eligible pool, carefully
The comparison every reader wants is roughly 200,000 fills across the two chains against the 3.8 million Part D enrollees KFF found met every eligibility rule, in the funnel above. It is also the comparison that is easiest to get wrong, so here is what it is not. It is not a participation rate. The numerator counts fills, the denominator counts people, the two were produced by different parties for different purposes, and the numerator covers only part of the pharmacy market. The denominator has its own problem: it is modelled on 2023 claims, as that section says.
NPR's own piece carries the conversion we are declining to make. A USC analyst quoted in it reads the same 200,000 as "somewhere between 5% and 10% of the eligible population", which requires treating every fill as a separate person and then roughly doubling the total for the chains that did not report. Neither step has a published basis. We are reporting the fills as fills.
The one people-shaped number in circulation is not a fill count either, and it does not close the gap. CMS Administrator Mehmet Oz said in a video posted to X on July 29, 2026 that 250,000 beneficiaries had signed up. NPR notes it is not clear whether those sign-ups cleared the prior authorization the Bridge requires, and a sign-up that is never approved never becomes a fill. Sign-ups, approvals and fills are three different counts, and nobody has published all three for the same date.
None of this changes the programme itself. CMS runs the Bridge between July 1, 2026 and December 31, 2027, which is what its own programme page states and what NPR reports. Nothing in this reporting extends it, and we are not modelling a year-end total from eight weeks of two retailers' dispensing.
Sources: Sydney Lupkin, NPR, August 26, 2026 (NPR appended a correction on August 27, 2026 about the authorship of a cited research paper; it does not touch the figures above), CMS Medicare GLP-1 Bridge, page last modified July 13, 2026, and KFF, June 29, 2026 for the eligible pool. All three fetched and read August 28, 2026.
Providers to watch for the Bridge
These telehealth providers carry Bridge-covered drugs on their menus (in some cases announced as coming soon, not yet live). Useful now for a consultation, and worth watching as the Bridge rolls out.
from $149/mo · 7.2/10
from $117/mo · 8.7/10
The official routes, and the authority CMS is using
Check eligibility and enrol through Medicare directly at Medicare.gov/glp1bridge, or call 1-800-MEDICARE (1-800-633-4227); TTY 1-877-486-2048. We are an independent comparison site and earn nothing from either.
- Your Part D plan does not have to opt in. CMS runs the Bridge outside the Part D benefit's coverage and payment flow, so sponsors carry no risk and do not have to join for you to get the drugs. If a plan tells you it does not participate, that is not a reason you cannot use the Bridge.
- One central processor handles it. For 2026 CMS uses a single central processor for prior authorisation, claims adjudication and payment to pharmacies, rather than routing through each plan.
- The legal basis is a demonstration authority, not a benefit expansion. Section 402(a)(1)(A) of the Social Security Amendments of 1967, made applicable to Part D by section 1860D-42(b) of the Social Security Act. That is why it has an end date and why the terms differ from ordinary Part D.
Quoted from the CMS Medicare GLP-1 Bridge FAQ, page last modified July 13, 2026, read August 4, 2026.
Frequently asked questions
Does the $50 copay count toward my Part D deductible?
No, and there are two further consequences CMS states plainly. Because Bridge drugs are furnished outside the Part D benefit payment flow, the Part D deductible does not apply, no part of the $50 counts toward your TrOOP (true out-of-pocket) costs, and there is no low-income subsidy provided for LIS beneficiaries. That last point matters most: if you normally get Extra Help with drug costs, it does not reduce the $50 here, so the Bridge is the same price for a low-income beneficiary as for anyone else. CMS confirmed all three on its Bridge FAQ page.
Will the $50 go up when I increase my dose?
No. The copay is flat at $50/month regardless of which dose you're on. Whether you're at the 0.25 mg Wegovy starting dose or the 2.4 mg maintenance dose, you pay $50.
Why is Zepbound KwikPen-only? What about the vials?
CMS restricted Zepbound to the KwikPen formulation for the Bridge. Single-dose vials and single-dose pens, which are often used by compounding pharmacies as reference products, are excluded. If you currently use vials, ask your prescriber about switching to KwikPen.
What does 'prior auth via Humana' mean for patients?
CMS designated Humana as the single central processor for all Bridge prior authorizations and claims, using the same LI NET infrastructure Humana already operates. In practice: your prescriber submits a prior auth the same way they submit any Part D PA. The claims then route through Humana's central processing regardless of which plan you're enrolled in.
Can I get the Bridge if I have Medicare Advantage?
Yes, if your Advantage plan includes Part D drug coverage (MA-PD). The Bridge is a CMS demonstration that runs separately from the plan, Part D sponsors don't have to opt in for their enrollees to access it.
What happens after December 31, 2027?
Unresolved, and be careful with what you read elsewhere. The BALANCE Model's Part D expansion was delayed in April 2026 rather than cancelled: CMS's own Bridge FAQ, last modified July 13, 2026, says the Bridge was extended through December 31, 2027 to let CMS collect GLP-1 utilisation data to share with Part D sponsors 'ahead of potential implementation of BALANCE in Part D'. So BALANCE is postponed and still live as a possibility. After December 2027 the options are that BALANCE arrives, CMS extends the Bridge again, Congress passes the Treat and Reduce Obesity Act, or coverage lapses. We update this page against the CMS source rather than against news coverage.